ANTI-PHENCYCLIDINE MONOCLONAL FAB FRAGMENTS MARKEDLY ALTER PHENCYCLIDINE PHARMACOKINETICS IN RATS

被引:0
|
作者
VALENTINE, JL
ARNOLD, LW
OWENS, SM
机构
[1] UNIV ARKANSAS MED SCI HOSP,COLL MED,DEPT PHARMACOL & TOXICOL,LITTLE ROCK,AR 72205
[2] UNIV N CAROLINA,SCH MED,DEPT MICROBIOL & IMMUNOL,CHAPEL HILL,NC 27599
来源
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS | 1994年 / 269卷 / 03期
关键词
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The purpose of these studies was to explore the use of phencyclidine (PCP)-specific high affinity antibodies as a possible treatment for phencyclidine toxicity. High affinity (K-d = 1.8 nM) anti-POP monoclonal Fab fragments were purified from papain digested anti-POP immunoglobulin produced in mouse ascites. Control animals (n = 5) received an i.v. bolus dose of 1 mg/kg of PCP, along with a tracer dose of 250 mu Cl of [H-3]PCP. Fab-treated rats (n = 5) also received this PCP dose. but at 2 hr after dosing (when PCP distribution was complete) they received an equimolar dose of anti-PCP Fab (50 mg). Within 5 min after the anti-POP Fab administration, serum [H-3]PCP concentrations increased approximately 60- to 100-fold. Fab treatment caused the [H-3]PCP volume of distribution at steady state to decrease from 12.6 +/- 3.0 liters/kg (mean +/- S.D.) in control animals to 0.6 +/- 0.2 liters/kg in the Fab-treated animals (about 5% of control values). Systemic clearance changed from 66.3 +/- 16.9 to 6.8 +/- 2.8 ml/min/kg (about 10% of control values). Because both volume of distribution and systemic clearance decreased to a similar degree, the terminal elimination half-life did not change significantly (3.9 hr in controls vs. 4.9 hr in treated animals, harmonic means). Renal clearance decreased from 1.8 +/- 0.6 to 0.62 +/- 0.17 ml/min/kg after Fab treatment. The anti-POP Fab caused the percentage of PCP recovered in urine to increase from 2.5 +/- 0.5 to 10.3 +/- 4.7%. The cumulative percentage of total radioactivity ([H-3]PCP plus H-3-metabolites) in the urine was not altered by the Fab treatment. Except for T-1/2 lambda z and total radioactivity in the urine, all pharmacokinetic parameters after anti-POP Fab treatment were significantly different from controls (Student's t test, P <.05). These dramatic changes in PCP pharmacokinetics suggest anti-POP Fab fragments could decrease PCP toxicity in overdose situations.
引用
收藏
页码:1079 / 1085
页数:7
相关论文
共 50 条
  • [41] Pharmacokinetics, biodistribution and dosimetry of anti-NCAM monoclonal antibody RNL-1 and its fragments in experimental lung cancer
    Mijnheere, EP
    Boerman, OC
    Poels, LG
    Slobbe, RL
    vanEys, GJJM
    Ramaekers, FCS
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 1996, 15 (01): : 11 - 18
  • [42] RADIOIMMUNODETECTION WITH TC-99M-LABELED ANTI-CEA MONOCLONAL-ANTIBODY FAB' FRAGMENTS - EXPERIENCE IN A LARGE COMMUNITY-HOSPITAL
    SWAYNE, LC
    GOLDENBERG, DM
    MACAULAY, R
    TRIVINO, JZ
    PINSKY, CM
    ANTIBODY IMMUNOCONJUGATES AND RADIOPHARMACEUTICALS, 1991, 4 (04): : 553 - 559
  • [43] Comparison of the antiplatelet agent potential of the whole molecule, F(ab')(2) and Fab fragments of humanized anti-GPIIb/IIIa monoclonal antibody in monkeys
    Kaku, S
    Yano, S
    Kawasaki, T
    Sakai, Y
    Suzuki, K
    Kawamura, K
    Masuho, Y
    Satoh, N
    Takenaka, T
    Landolfi, NF
    Co, MS
    GENERAL PHARMACOLOGY-THE VASCULAR SYSTEM, 1996, 27 (03): : 435 - 439
  • [44] THE INTERACTION OF 2 POLYSACCHARIDES CONTAINING BETA-1,6-LINKED GALACTOPYRANOSYL RESIDUES WITH 2 MONOCLONAL ANTI-GALACTAN IMMUNOGLOBULIN FAB' FRAGMENTS
    ROY, A
    MANJULA, BN
    GLAUDEMANS, CPJ
    MOLECULAR IMMUNOLOGY, 1981, 18 (02) : 79 - 84
  • [45] Prenatal phencyclidine induces heightened neurodegeneration in rats in some brain regions, especially during 2nd trimester, but possible anti-apoptotic effects in others
    Jebelli, AK
    Doan, N
    Ellison, G
    PHARMACOLOGY & TOXICOLOGY, 2002, 90 (01): : 20 - 25
  • [46] PENETRATION AND BINDING OF RADIOLABELED ANTI-CEA MONOCLONAL-ANTIBODIES AND THEIR F(AB')2 AND FAB FRAGMENTS IN HUMAN-COLON MULTICELLULAR TUMOR SPHEROIDS
    SUTHERLAND, R
    BUCHEGGER, F
    VACCA, A
    SCHREYER, M
    MACH, JP
    CANCER DRUG DELIVERY, 1985, 2 (03): : 239 - 239
  • [47] I-123 F(AB')2 AND FAB FRAGMENTS OF ANTI-CEA LABELED MONOCLONAL-ANTIBODIES - BIOKINETICS IN PATIENTS WITH COLORECTAL-CARCINOMA
    DELALOYE, B
    BISCHOFDELALOYE, A
    BUCHEGGER, F
    VONFLIEDNER, V
    MACH, JP
    JOURNAL OF NUCLEAR MEDICINE, 1986, 27 (06) : 1019 - 1020
  • [48] Pharmacokinetics in rabbits and anti-sphingomyelinase D neutralizing power of Fab, F(ab′)2, IgG and IgG(T) fragments from hyper immune equine plasma
    Vazquez, H.
    Olvera, F.
    Paniagua-Solis, J.
    Alagon, A.
    Sevcik, C.
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2010, 10 (04) : 447 - 454
  • [49] The fab fragment of a novel anti-GPVI monoclonal antibody, OM4, reduces in vivo thrombosis without bleeding risk in rats
    Li, Haiquan
    Lockyer, Simon
    Concepcion, Alice
    Gong, Xiaoqi
    Takizawa, Hisao
    Guertin, Moe
    Matsumoto, Yutaka
    Kambayashi, Junichi
    Tandon, Narendra N.
    Liu, Yongge
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2007, 27 (05) : 1199 - 1205
  • [50] ALTERED PHARMACOKINETIC AND TUMOR-LOCALIZATION PROPERTIES OF FAB' FRAGMENTS OF A MURINE MONOCLONAL ANTI-CEA ANTIBODY BY COVALENT MODIFICATION WITH LOW-MOLECULAR-WEIGHT DEXTRAN
    FAGNANI, R
    HALPERN, S
    HAGAN, M
    NUCLEAR MEDICINE COMMUNICATIONS, 1995, 16 (05) : 362 - 369